H E A LT H C A R E S E L E C T P O R T F O L I O
SERIES 45
The health care industry has been responsible for several discoveries that have led to new drugs and products designed to better serve the masses, especially the aging population. These discoveries
have improved the quality of life and the life expectancy of millions. More recent research, relating to areas such as genomics, is providing avenues of growth never before imagined. Debilitating
diseases, previously untreatable, are now often manageable or even curable. Over the period of 2016-2025, it is projected that health care spending will grow at an average rate of 5.6% annually. In
addition, health care spending is anticipated to grow 1.2% faster than GDP per year over the same period; as a result, the health care share of GDP is expected to increase from 17.8% in 2015 to
19.9% by 2025.1
1
CMS.gov
PORTFOLIO SUMMARY
MEDIC AL PRODUC TS & SUPPLIES
In 1988, approximately 20% of all surgeries were performed on an outpatient basis, compared to
approximately 60-70% today.2 Technological advances made to medical devices have helped fuel this
trend. New devices have been developed that are less invasive, often eliminating the need for extensive
inpatient hospital stays. We believe that further advances may also serve to keep costs down and create
demand for medical products, devices and supplies.
2
AARP.org
Initial Date of Deposit:
Initial Public Offering Price:
Portfolio Ending Date:
A variety of new and improved medicines have expanded the options for doctors and patients, allowing
previously untreatable or poorly treated illnesses to be treated effectively and giving patients and
physicians new opportunities to prevent and manage disease. Managed care providers encourage the
use of pharmaceuticals because they are a relatively inexpensive and less invasive form of treatment.
$10.00 per Unit
5/17/2019
CUSIPs:
30302Q 781(c) 799(r)
Fee Accounts CUSIPs:
30302Q 807(c) 815(r)
Ticker Symbol:
BIOTECHNOLOGY & PHARMACEUTIC ALS
5/17/2017
FDNAVX
PORTFOLIO OBJEC TIVE
This unit investment trust seeks above-average capital appreciation; however, there is
no assurance the objective will be met.
You should consider the portfolio’s investment objective, risks, and charges
and expenses carefully before investing. Contact your financial advisor or
call First Trust Portfolios L.P. at the number listed below to request a
prospectus, which contains this and other information about the portfolio.
Read it carefully before you invest.
NATIONAL HEALTH EXPENDITURES
C ALENDAR YEARS 2009-2025 (IN TRILLIONS)
$6
$5
$4
$3
$2
$1
$0
'09 '10 '11 '12 '13 '14 '15 '16* '17* '18* '19* '20* '21* '22* '23* '24* '25*
Source: CMS.gov
*Estimated
RISK CONSIDERATIONS
An investment in this unmanaged unit investment trust should be made with an understanding of
the risks involved with owning common stocks, such as an economic recession and the possible
deterioration of either the financial condition of the issuers of the equity securities or the general
condition of the stock market.
You should be aware that the portfolio is concentrated in stocks in the health care sector which
involves additional risks, including limited diversification. The companies engaged in the health
care sector are subject to fierce competition, high research and development costs, governmental
regulations, loss of patent protection, and changing consumer spending trends.
An investment in foreign equities should be made with an understanding of the additional risks
involved with foreign issuers, such as currency fluctuations, political risk, withholding, the lack of
adequate financial information, and exchange control restrictions impacting foreign issuers.
This UIT is a buy and hold strategy and investors should consider their ability to hold the trust
until maturity. There may be tax consequences unless units are purchased in an IRA or other
qualified plan.
First Trust Portfolios L.P. | Member SIPC | Member FINRA
An investment in a portfolio containing small-cap and mid-cap companies is subject to
additional risks, as the share prices of small-cap companies and certain mid-cap companies are
often more volatile than those of larger companies due to several factors, including limited
trading volumes, products, financial resources, management inexperience and less publicly
available information.
The value of the securities held by the trust may be subject to steep declines or increased volatility
due to changes in performance or perception of the issuers.
The information presented is not intended to constitute an investment recommendation for, or
advice to, any specific person. By providing this information, First Trust is not undertaking to give
advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First
Trust has no knowledge of and has not been provided any information regarding any investor.
Financial advisors must determine whether particular investments are appropriate for their
clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment
risks independently and is responsible for exercising independent judgment with respect to its
retirement plan clients.
1-800-621-1675 | www.ftportfolios.com
SERIES 45
H E A LT H C A R E S E L E C T P O R T F O L I O
HOLDINGS
TICKER COMPANY NAME
BIOTECHNOLOGY
ABBV
AbbVie Inc.
ALXN
Alexion Pharmaceuticals, Inc.
AMGN
Amgen Inc.
BIIB
Biogen Inc.
CELG
Celgene Corporation
GILD
Gilead Sciences, Inc.
REGN
Regeneron Pharmaceuticals, Inc.
SHPG
Shire Plc
HEALTH CARE DISTRIBUTORS
ABC
AmerisourceBergen Corporation
CAH
Cardinal Health, Inc.
MCK
McKesson Corporation
HEALTH CARE EQUIPMENT
BSX
Boston Scientific Corporation
MDT
Medtronic Plc
SYK
Stryker Corporation
ZBH
Zimmer Biomet Holdings, Inc.
HEALTH CARE FACILITIES
HCA
HCA Healthcare Inc.
HEALTH CARE SUPPLIES
ALGN
Align Technology, Inc.
COO
The Cooper Companies, Inc.
LIFE SCIENCES TOOLS & SERVICES
ICLR
ICON Plc
TMO
Thermo Fisher Scientific Inc.
MANAGED HEALTH CARE
AET
Aetna Inc.
ANTM
Anthem, Inc.
CNC
Centene Corporation
UNH
UnitedHealth Group Incorporated
PHARMACEUTICALS
AGN
Allergan Plc
LLY
Eli Lilly and Company
JNJ
Johnson & Johnson
MRK
Merck & Co., Inc.
PFE
Pfizer Inc.
RHHBY
Roche Holding AG
SALES CHARGES (BASED ON A $10 PUBLIC OFFERING PRICE)
PRICE*
STANDARD ACCOUNTS
Transactional Sales Charges:
Initial 1.00%
Deferred 2.45%
0.50%
3.95%
$66.85
120.30
159.99
257.64
119.36
65.72
454.75
184.79
Creation & Development Fee:
Maximum Sales Charge:
89.12
72.63
144.92
The creation and development fee is a charge of $.050 per unit collected at the end of the initial offering
period. If the price you pay exceeds $10 per unit, the creation and development fee will be less than 0.50%;
if the price you pay is less than $10 per unit, the creation and development fee will exceed 0.50%.
The deferred sales charge will be deducted in three monthly installments commencing 8/18/17.
FEE/WRAP ACCOUNTS*
Maximum Sales Charge:
0.50%
*The maximum sales charge for investors in fee accounts consists of the creation and development fee.
Investors in fee accounts are not assessed any transactional sales charges. Standard accounts sales charges
apply to units purchased as an ineligible asset.
In addition to the sales charges listed, UITs are subject to annual operating expenses and organization costs.
26.48
83.94
134.77
119.78
83.49
138.61
210.46
88.48
172.27
VOLUME DISCOUNTS
If you invest at least $50,000, the maximum sales charge is reduced as follows:
INITIAL PURCHASES
$50,000 but less than $100,000
$100,000 but less than $250,000
$250,000 but less than $500,000
$500,000 but less than $1,000,000
$1,000,000 or more
HOLDINGS ST YLE ANALYSIS
l Large-Cap Growth
l Large-Cap Value
l Mid-Cap Growth
l Mid-Cap Value
141.86
180.81
76.44
168.12
224.55
78.99
127.77
63.79
32.60
34.38
MAXIMUM SALES CHARGE
3.70%
3.45%
3.10%
2.95%
2.45%
53.35%
33.29%
10.04%
3.32%
HOLDINGS SEC TOR ANALYSIS
l Biotechnology
l Health Care Distributors
l Health Care Equipment
l Health Care Facilities
l Health Care Supplies
l Life Sciences Tools & Services
l Managed Health Care
l Pharmaceuticals
*As of the close of business on 5/16/17. Market values are for reference only and are not indicative of your
individual cost basis.
26.65%
9.99%
13.31%
3.35%
6.69%
6.66%
13.37%
19.98%
HOLDINGS COMPOSITION
U.S. Stocks:
Non-U.S. Stocks:
83.35%
16.65%
The holdings characteristics of the portfolio are determined as of the initial date of deposit and may differ
slightly from those indicated above due to the requirement that only whole shares be purchased for the
portfolio and will likely vary thereafter due to market fluctuations in the underlying securities. For a
complete description of these characteristics refer to the prospectus.
NOT FDIC INSURED | NOT BANK GUARANTEED | MAY LOSE VALUE
HC2YFS450617